Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -4.60% and closed the trade at $ 1.66. The company recorded a trading capacity of 6.3 million shares above its three months average daily volume of 1.45 million shares. During the last trade, shares reached to high price of $1.79 and touched the low price of $1.62. The stock’s 50-day moving average is noted at $1.63 and its 200-day moving average is stands at $1.71.
Additionally, the company has EPS of -0.44. The company has market capitalization of $403.80M.
Currently Arena Pharmaceuticals, Inc. (ARNA) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “3″ Analysts”. “0” rated “Sell” for the company. “4” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $4.50 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $6.00 however minimum price target advised by analysts is $3.50. The Median price target for the stock is measured at $4.00.
Presently, Analysts decided consensus EPS estimate of $-0.07 for present quarter and one month ago projected EPS estimate was at $-0.06. If we take a look at back 3 month ago, consensus EPS estimate was $-0.08.
A current consensus EPS estimate for next quarter is at $-0.08 and 3 month ago EPS forecast was $-0.08. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.09.
For current fiscal year, most recent EPS estimate is set at $-0.35 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.34. During period one month ago, consensus EPS forecast was decided at $-0.35.
A current consensus EPS projection for next fiscal year is observed at $-0.33 and one month ago consensus EPS forecast was at $-0.33. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.32 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 2 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 4 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 2 said a “Buy Rating” and 0 announced “Overweight Rating”. 5 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.